Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells

被引:59
|
作者
Nishizaki, M
Sasaki, J
Fang, BL
Atkinson, EN
Minna, JD
Roth, JA
Ji, L
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 445, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
[3] Univ Texas, SW Med Ctr, Dept Internal Med & Pharmacol, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA
关键词
D O I
10.1158/0008-5472.CAN-04-0195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrations of the tumor suppressor genes FHIT and p53 are frequently associated with a wide range of human cancers, including lung cancer. We studied the combined effects of FHIT and p53 proteins on tumor cell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and on tumor growth in animal models by adenoviral vector-mediated cotransfer of wild-type FHIT and p53 genes. We found that the coexpression of FHIT and p53 synergistically inhibited tumor cell proliferation in NSCLC cells in vitro and suppressed the growth of human tumor xenografts in nude mice. Furthermore, we found that this synergistic inhibition of tumor cell growth corresponded with the FHIT-mediated inactivation of MDM2, which thereby blocked the association of MDM2 with p53, thus stabilizing the p53 protein. Our results therefore reveal a novel molecular mechanism consisting of FHIT-mediated tumor suppression and the interaction of FHIT with other cellular components in the pathways regulating p53 activity. These findings show that combination treatment with synergistic tumor-suppressing gene therapy such as Ad-FHIT and Ad-p53 may be an effective therapeutic strategy for NSCLC and other cancers.
引用
收藏
页码:5745 / 5752
页数:8
相关论文
共 50 条
  • [21] P53, FHIT, K-RAS GENE MUTATIONS ARE ASSOCIATED WITH SMOKING IN NON-SMALL CELL LUNG CANCER BY META-ANALYSIS
    Ma, L.
    Zhao, M-J
    Wang, Q. L. Xiu-Lin
    Wang, X-G
    RESPIROLOGY, 2011, 16 : 133 - 136
  • [22] Teroxirone inhibited growth of human non-small cell lung cancer cells by activating p53
    Wang, Jing-Ping
    Lin, Kai-Han
    Liu, Chun-Yen
    Yu, Ya-Chu
    Wu, Pei-Tsun
    Chiu, Chien-Chih
    Su, Chun-Li
    Chen, Kwun-Min
    Fang, Kang
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2013, 273 (01) : 110 - 120
  • [23] Growth inhibitory role of the p53 activator SCH 529074 in non-small cell lung cancer cells expressing mutant p53
    Nenkov, Miljana
    Ma, Yunxia
    Haase, Daniela
    Zhou, Zhongwei
    Li, Yong
    Petersen, Iver
    Lu, Guanghua
    Chen, Yuan
    ONCOLOGY REPORTS, 2020, 43 (06) : 2073 - 2082
  • [24] The p53 codon 72 Proline allele is associated with p53 gene mutations in non-small cell lung cancer
    Hu, YC
    McDermott, MP
    Ahrendt, SA
    CLINICAL CANCER RESEARCH, 2005, 11 (07) : 2502 - 2509
  • [25] p53 and MDM2 isoforms in blood from lung cancer patients
    Gonzalez-Avila, Georgina
    Biol, Javier Delgado
    Martinez, Luis M.
    Ramos, Carlos
    Sommer, Bettina
    EXPERIMENTAL LUNG RESEARCH, 2007, 33 (05) : 245 - 258
  • [26] The expression of GST isoenzymes and p53 in non-small cell lung cancer
    Oguztuzun, Serpil
    Aydin, Mehtap
    Demirag, Funda
    Yazici, Ulku
    Ozhavzali, Muzeyyen
    Kilic, Murat
    Iscan, Mesude
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2010, 48 (01) : 122 - 127
  • [27] Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells
    Jin, Longyu
    Li, Cui
    Xu, Yan
    Wang, Li
    Liu, Jianxin
    Wang, Dianjun
    Hong, Cao
    Jiang, Zhibing
    Ma, Yuchao
    Chen, Qian
    Yu, Fenglei
    ONCOLOGY REPORTS, 2013, 29 (05) : 1983 - 1990
  • [28] Clinical significance of p53 in non-small cell lung cancer (Review)
    Komiya, T
    Hirashima, T
    Kawase, I
    ONCOLOGY REPORTS, 1999, 6 (01) : 19 - 28
  • [29] TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway
    Ying Xing
    Yuechao Liu
    Tianbo Liu
    Qingwei Meng
    Hailing Lu
    Wei Liu
    Jing Hu
    Chunhong Li
    Mengru Cao
    Shi Yan
    Jian Huang
    Ting Wang
    Li Cai
    Cell Communication and Signaling, 16
  • [30] TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway
    Xing, Ying
    Liu, Yuechao
    Liu, Tianbo
    Meng, Qingwei
    Lu, Hailing
    Liu, Wei
    Hu, Jing
    Li, Chunhong
    Cao, Mengru
    Yan, Shi
    Huang, Jian
    Wang, Ting
    Cai, Li
    CELL COMMUNICATION AND SIGNALING, 2018, 16